LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today results from a new clinical study evaluating prescription strength Hydroquinone/L-Ascorbic Acid Treatment System for normal to oily skin (Obagi-C® Rx). The system provided improvement in overall facial appearance as well as increased patient satisfaction.
“The results of this study clearly demonstrate that the Hydroquinone/L-Ascorbic Acid Treatment System for normal to oily skin is a great way for physicians to help ameliorate early signs of photodamage in younger-looking skin and help prevent further photodamage,” says Suzanne Bruce, MD, of Suzanne Bruce & Associates, PA in Houston, TX. “As a physician, I want to recommend a skin care regimen that has a proven ability to give patients the results they desire.”
At the conclusion of the study, 100% of patients reported the system was good, very good, or excellent compared with other skin treatments they had used before. In addition, statistically significant benefits were seen in hyperpigmentation and skin laxity as well as improved levels of skin texture and fine lines and wrinkles. Similarly, the Hydroquinone/L-Ascorbic Acid Treatment System was clinically proven to increase patient satisfaction. All of the patients were either Satisfied or Very Satisfied with their overall facial appearance. This data was presented at the 22nd World Congress of Dermatology (WCD) in May 2011.
“I have been administering Hydroquinone/L-Ascorbic Acid Treatments for years,” said Suzanne Bruce, MD, of Suzanne Bruce & Associates, PA in Houston, TX. “However, by administering a 4% HQ with L-ascorbic acid system treatment, my patients are more pleased with their overall results and appreciate that the treatment offers continued improvement to their facial appearance.”
Participants in the clinical study had a mean age of 32 years and exhibited minimal to mild photodamage. Over the course of the 12 week trial, 34 participants enrolled, with 30 (88%) completing the study.
About Obagi Medical Products, Inc.
Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medical’s portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition &Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, Obagi ELASTIderm® Eye Treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, a formulation of Obagi CLENZIderm M.D. Systems for normal to dry skin, and Obagi ELASTIderm Décolletage System, Obagi Rosaclear® System, Obagi ELASTILash™ Eyelash Solution, Obagi Blue Peel RADIANCETM, and Nu-Derm® Sun Shield SPF 50. Visit www.obagi.com for information.
Blue Peel RADIANCE, ELASTIlash and Penetrating Therapeutics are trademarks, and Obagi, Blue Peel, Condition & Enhance, ELASTIderm, Nu-Derm, Obagi-C, Obagi CLENZIderm and Rosaclear are registered trademarks, of Obagi Medical Products, Inc. and/or its affiliates in the United States and certain other countries.